Semaglutide for the Treatment of Obesity in Children 6 to

赛马鲁肽 医学 安慰剂 置信区间 肥胖 体质指数 随机对照试验 儿科 物理疗法 临床终点 减肥 儿童肥胖 内科学 随机化 安慰剂组 临床试验 外科 重量变化 体重 体重增加 超重
作者
Ania M. Jastreboff,Nina Majlund Harder-Lauridsen,Michelle Van Name,Antje Körner,Aaron S. Kelly,Daniel Weghuber,Jens-Christian Holm,Christine Frithioff‐Bøjsøe,Shilpa Middolu,Tina Buch,Martin Wabitsch
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
标识
DOI:10.1056/nejmoa2604058
摘要

BACKGROUND: Childhood obesity is a chronic, neurometabolic disease with limited options for medical treatments that are efficacious and durable. Once-weekly subcutaneous semaglutide is approved for the treatment of obesity in adolescents and adults, but data for its use in young children are lacking. METHODS: We conducted a phase 3, double-blind, randomized, placebo-controlled trial involving children (6 to <12 years of age) with obesity. Participants were randomly assigned in a 2:1 ratio to receive once-weekly subcutaneous semaglutide or placebo for a period of 104 weeks, after which participants stopped taking semaglutide or placebo for a 7-week washout period. Both groups received counseling for lifestyle modification. The primary end point was the percent change in the body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) from baseline to week 68. The confirmatory secondary end point was a reduction in BMI category at week 68. RESULTS: Among 167 children who underwent randomization, 112 were assigned to receive semaglutide and 55 to receive placebo. At week 68, the mean percent change in BMI was -13.5% with semaglutide and 2.7% with placebo (estimated between-group difference, -16.2 percentage points; 95% confidence interval [CI], -19.4 to -12.9; P<0.001). The percent change in BMI at week 104 was -9.4% with semaglutide and 8.4% with placebo (between-group difference, -17.8 percentage points; 95% CI, -22.2 to -13.3). At week 68, a reduction in BMI category had occurred in 79% of the participants in the semaglutide group and in 23% of those in the placebo group (odds ratio, 7.8; 95% CI, 3.5 to 17.6; P<0.001), with the BMI below the threshold for obesity (the 95th percentile for age and sex) in 38% of the participants who received semaglutide and in 2% of those who received placebo. Adverse events occurred in 96% of the participants receiving semaglutide and in 93% of those receiving placebo. Gastrointestinal adverse events were the most common, occurred more frequently with semaglutide than with placebo, and led to discontinuation in 1 participant in the semaglutide group. CONCLUSIONS: Among children (6 to <12 years of age) with obesity, treatment with semaglutide for 68 weeks resulted in a significantly greater mean percent reduction in BMI than placebo. (Funded by Novo Nordisk; STEP Young ClinicalTrials.gov number, NCT05726227.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
NexusExplorer的应助被iieee采纳,获得10
刚刚
Betsy发布了新的文献求助10
1秒前
1秒前
XXDNC完成签到,获得积分10
1秒前
烂漫的金针菇关注了科研通微信公众号
2秒前
ydlfvya完成签到,获得积分10
2秒前
hermit完成签到,获得积分10
2秒前
大尾巴鱼发布了新的文献求助10
2秒前
超级的初蓝完成签到 ,获得积分10
3秒前
3秒前
4秒前
www2发布了新的文献求助10
4秒前
4秒前
WMY发布了新的文献求助10
5秒前
香香香发布了新的文献求助10
5秒前
朱伟完成签到,获得积分10
5秒前
6秒前
6秒前
Penn完成签到,获得积分10
6秒前
可爱的函函的应助被obcx采纳,获得10
6秒前
爆米花的应助被XXDNC采纳,获得30
7秒前
烟花的应助被15331970326采纳,获得10
8秒前
8秒前
动听衬衫发布了新的文献求助10
9秒前
蛋又白发布了新的文献求助10
9秒前
秀丽二娘完成签到,获得积分10
10秒前
陈天降低完成签到,获得积分10
10秒前
donkey发布了新的文献求助10
10秒前
赵浩楠完成签到,获得积分10
10秒前
zane完成签到,获得积分10
11秒前
11秒前
顺利的妖妖完成签到 ,获得积分10
11秒前
XY发布了新的文献求助10
11秒前
zhang03完成签到,获得积分10
12秒前
13秒前
充电宝的应助被zclm采纳,获得10
13秒前
13秒前
caocao发布了新的文献求助10
14秒前
zuuyo完成签到,获得积分20
15秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187748
求助须知:如何正确求助?哪些是违规求助? 9575825
关于积分的说明 21843288
捐赠科研通 7785628
什么是DOI,文献DOI怎么找? 3435097
关于科研通互助平台的介绍 2559495
邀请新用户注册赠送积分活动 2482000